Opinion

Video

Genetic Testing in Metastatic Prostate Cancer: Key Insights on Germline and Somatic Mutations

Key Takeaways

  • Talazoparib in the TALAPRO-1 trial improved progression-free survival and overall response rates in metastatic prostate cancer with specific genetic alterations.
  • Rucaparib in the TRITON3 trial showed superior progression-free survival compared to standard treatments, highlighting its efficacy in targeted patient populations.
SHOW MORE

Panelists discuss how PARP inhibitor monotherapy trials like TALAPRO-1 (talazoparib) and TRITON-3 (rucaparib) have demonstrated efficacy and safety in treating metastatic prostate cancer patients with homologous recombination repair gene alterations, providing important insights into targeted therapy options for this specific patient population.

Video Content above is prompted by the following:

  • Discuss efficacy and safety findings from monotherapy trials of PARP inhibitors in metastatic prostate cancer harboring homologous recombination repair (gene alterations.
    • TALAPRO-1 trial (talazoparib), NCT03148795
    • TRITON3 trial (rucaparib), NCT02975934.
Related Videos
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Michael Jenson, PA-C, answers a question during a Zoom video interview
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
Oliver Sartor, MD, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.